MedPath

Medical University of Vienna

Medical University of Vienna logo
πŸ‡¦πŸ‡ΉAustria
Ownership
Private
Established
1365-01-01
Employees
1K
Market Cap
-
Website
http://www.meduniwien.ac.at

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

Conditions
Uterine Cervical Neoplasms
First Posted Date
2006-10-17
Last Posted Date
2006-10-17
Lead Sponsor
Medical University of Vienna
Target Recruit Count
25
Registration Number
NCT00388687
Locations
πŸ‡¦πŸ‡Ή

Medical Universitiy of Vienna, Vienna, Austria

πŸ‡¦πŸ‡Ή

Medical University of Vienna, Vienna, Austria

Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study

Phase 2
Completed
Conditions
Myocardial Infarction
Interventions
Procedure: Bone marrow-derived stem cells implantation
First Posted Date
2006-10-06
Last Posted Date
2010-01-22
Lead Sponsor
Medical University of Vienna
Target Recruit Count
116
Registration Number
NCT00384982
Locations
πŸ‡¦πŸ‡Ή

Department of Cardiology, Medical University of Vienna, Vienna, Austria

Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients

Phase 3
Completed
Conditions
Cancer
First Posted Date
2006-09-12
Last Posted Date
2009-09-18
Lead Sponsor
Medical University of Vienna
Registration Number
NCT00375076
Locations
πŸ‡¦πŸ‡Ή

Medical University of Vienna, Vienna, Austria

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Phase 3
Completed
Conditions
Hemophilia A
First Posted Date
2006-09-12
Last Posted Date
2007-04-20
Lead Sponsor
Medical University of Vienna
Registration Number
NCT00375323
Locations
πŸ‡¦πŸ‡Ή

Medical University of Vienna, Vienna, Austria

Velcade in MALT Lymphoma Patients

Phase 2
Completed
Conditions
MALT Lymphoma
First Posted Date
2006-09-08
Last Posted Date
2013-11-27
Lead Sponsor
Medical University of Vienna
Target Recruit Count
16
Registration Number
NCT00373906

Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients

Phase 2
Completed
Conditions
MALT Lymphoma
First Posted Date
2006-09-08
Last Posted Date
2009-06-18
Lead Sponsor
Medical University of Vienna
Target Recruit Count
8
Registration Number
NCT00373646
Locations
πŸ‡¦πŸ‡Ή

Department of Internal Medicine I, Vienna, Austria

TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )

Phase 2
Terminated
Conditions
Lupus Erythematosus, Systemic
Lupus Nephritis
Interventions
Drug: placebo
First Posted Date
2006-08-24
Last Posted Date
2009-10-05
Lead Sponsor
Medical University of Vienna
Target Recruit Count
1
Registration Number
NCT00368264
Locations
πŸ‡©πŸ‡ͺ

Internal Medicine III, University of Erlangen, Erlangen, Germany

πŸ‡¦πŸ‡Ή

Internal Medicine II, Hietzing Hospital, Vienna, Austria

πŸ‡©πŸ‡ͺ

Rheumatology, Charite, Berlin, Germany

and more 6 locations

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer

Phase 1
Conditions
Metastatic Breast Cancer
First Posted Date
2006-08-22
Last Posted Date
2010-09-28
Lead Sponsor
Medical University of Vienna
Target Recruit Count
32
Registration Number
NCT00367250
Locations
πŸ‡¦πŸ‡Ή

Dept of Internal Medicine, Vienna, Austria

Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers

Completed
Conditions
Sepsis
First Posted Date
2006-08-03
Last Posted Date
2007-12-11
Lead Sponsor
Medical University of Vienna
Target Recruit Count
10
Registration Number
NCT00360048
Locations
πŸ‡¦πŸ‡Ή

Medical University of Vienna, Vienna, Austria

Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh

Phase 2
Completed
Conditions
Uncomplicated Falciparum Malaria
Interventions
First Posted Date
2006-07-25
Last Posted Date
2012-11-01
Lead Sponsor
Medical University of Vienna
Target Recruit Count
228
Registration Number
NCT00356005
Locations
πŸ‡§πŸ‡©

Sadar Hospital, Bandarban, Bangladesh

Β© Copyright 2025. All Rights Reserved by MedPath